



PATENT  
Customer No. 22,852  
Attorney Docket No. 06478.1441-01

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: )  
 )  
Claude NÉGRIER et al. )  
 )  
Application No.: 09/880,887 ) Group Art Unit: 1632  
 )  
Filed: June 15, 2001 ) Examiner: Q. Nguyen  
 )  
For: MODIFIED FACTOR VIII cDNA )

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits after the filing of a request for continued examination under 37 C.F.R. § 1.114 for the above-referenced application.

Copies of the listed documents, including any copending patent applications, are attached.

Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

English translations of the non-English documents are enclosed.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER <sup>LLP</sup>

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: February 9, 2004

By: \_\_\_\_\_

  
Sanya Sukduang  
Reg. No. 46,390

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com



OMB No. 0651-0011

**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

Atty. Docket No.	06478.1441-01	Serial No.	09/880,887
Applicant	Claude NÉGRIER et al.		
Filing Date	June 15, 2001	Group:	1636

**U.S. PATENT DOCUMENTS**

Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate
	5,112,950	05/12/1992	Meulien et al.	530	383	06/26/1991
	6,399,587 B1	06/04/2002	Mehtali et al.	514	44	12/02/1999
	6,271,025	08/07/2001	Negrier et al.	435	320.1	03/16/2000


**FOREIGN PATENT DOCUMENTS**

Document Number	Date	Country	Class	Sub Class	Translation Yes or No
WO 92/16557	10/01/1992	PCT			
WO 94/29471	12/22/1994	PCT	A1		
EP 0 197 901 B1	10/15/1986	Europe			
EP 0 295 597 A2	12/21/1988	Europe			Engl. Abstract encl.
EP 0 303 540 B1	02/15/1989	Europe			Engl. Abstract encl.
WO 87/04187	07/16/1987	PCT			
WO 88/00831	02/11/1988	PCT			
EP 1 038 959 A1	09/27/2000	Europe			
EP 1 048 726 A2	10/02/2000	Europe			
EP 1 231 220 A1	08/14/2002	Europe			

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

Abstract, WO 98/55639 (12/10/98).
ANDERSSON, L.O. et al., "Isolation and characterization of human factor VIII: Molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 83: 2979-2983, (1986).
BRINKHAUS et al., "Purified human factor VIII procoagulant protein: Comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 82: 8752-8756 (1985).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

Atty. Docket No.	06478.1441-01	Serial No.	09/880,887
Applicant	Claude NÉGRIER et al.		
Filing Date	June 15, 2001	Group:	1636

	BUCHMAN et al., "Comparison of Intron-Dependent and Intron-Independent Gene Expression," <i>Molecular and Cellular Biology</i> , Vol. 8(10):4395-4405 (1988).
	BURKE et al., "The Functional Domains of Coagulation Factor VIII:C*," <i>J. Biol. Chem.</i> , Vol. 261: 12574-12578 (1986)
	CONNELLY et al., "High-Level Tissue-Specific Expression of Functional Human Factor VIII in Mice", <i>Human Gene Therapy</i> , Vol. 7(2):183-195 (1996)
	Derwent abstract of EP 0 295 597 A2
	Derwent abstract of EP 0 303 540 B1
	EATON et al., "Construction and Characterization of an Active Factor VIII Variant Lacking the Central One-Third of the Molecule," <i>American Chemical Society</i> , Vol. 25(26): 8343-8347 (1986).
	FALLAUX, F.J. et al., "The Human Clotting Factor VIII cDNA Contains an Autonomously Replicating Sequence Consensus-and Matrix Attachment Region-like Sequence that Binds a Nuclear Factor, Represses Heterologous Gene Expression, and Mediates the Transcriptional Effects of Sodium Butyrate," <i>Mol. Cell. Biol.</i> , Vol 16: 4264-4272 (1996).
	FOSTER, P.A., et al., "Factor VIII Structure and Function," <i>Blood Reviews</i> , Vol. 3: 180-191(1989).
	GITSCHIER, J. et al., "Characterization of the human factor VIII gene," <i>Nature</i> , Vol. 312: 326-330 (1984).
	HOEBEN, R.C. et al., "Toward gene therapy in haemophilia: A retrovirus-mediated transfer of a factor VIII gene into murine haematopoietic progenitor cells," <i>Thrombosis and Haemostasis</i> , Vol. 67(3): 341-345 (1992).
	KAUFMAN, R.J. "Biological Regulation of Factor-VIII Activity," <i>Ann. Rev. of Medicine</i> , Vol. 43: 325-339 (1992).
	KAUFMAN, R.J. et al., "Effects of von Willebrand Factor Coexpression on the Synthesis and Secretion of Factor VIII in Chinese Hamster Ovary Cells," <i>Mol. Cell. Biol.</i> , Vol. 9: 1233-1242 (1989).
	KIM et al., "Heterologous Introns Enhanced Expression of Human Lactoferrin cDNA in Mouse Mammary Epithelial Cells," <i>J. Biochem. Mol. Biol.</i> , Vol. 28(1):57-61 (1995).
	KOEBERL, D.D., et al., "Sequence within the Coding Regions of Clotting Factor VIII and CFTR Block Transcription Elongation," <i>Human Gene Therapy</i> , Vol. 6: 469-479 (1995).
	LAEMMLI, U.K. "Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4," <i>Nature</i> , Vol. 227: 680-685 (1970).

Examiner	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
Form PTO 1449 Page 2 of 4	Patent and Trademark Office - U.S. Department of Commerce



**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

Atty. Docket No.	06478.1441-01	Serial No.	09/880,887
Applicant	Claude NÉGRIER et al.		
Filing Date	June 15, 2001	Group:	1636

	LAGNER et al., "Synthesis of Biologically Active Deletion Mutants of Human Factor VIII:C," <i>Behring Inst. Mitt.</i> , Vol. 82:16-25 (1988).
	LIND, Peter et al., "Novel Forms of B-Domain-Deleted Recombinant Factor VIII Molecules Construction and Biochemical Characterization," <i>Bur. J. Biochemistry</i> , Vol. 232:19-27 (1995).
	LYNCH, C.M., et al., "Sequences in the Coding Region of Clotting Factor VIII Act as Dominant Inhibitors of RNA Accumulation and Protein Production," <i>Human Gene Therapy</i> , Vol. 4: 8537-8544 (1998).
	MEULIEN et al., "A new recombinant procoagulant protein derived from the cDNA encoding human factor VIII," <i>Protein Engineering</i> , Vol. 2(4):301-306 (1988).
	NICHOLS, W.C., et al., "Mutations in the ER-Golgi Intermediate Compartment Protein ERGIC-53 cause Combined Deficiency of Coagulation Factors V and VIII," <i>Cell</i> , Vol. 93: 61-70 (1998).
	PAVIRANI et al., "Two Independent Domains of Factor VIII Co-Expressed Using Recombinant Vaccinia Viruses Have Procoagulant Activity," <i>Biochem. Biophys. Res. Comm.</i> , Vol. 145 (1):234-240 (1987)
	PIPE, S.W. et al., "Differential Interaction of Coagulation Factor VIII and Factor V with Protein Chaperones Calnexin and Calreticulin," <i>J. Biol. Chem.</i> , Vol. 273: 8537-8544 (1998).
	PITTMAN, D.D. et al., "Biochemical, Immunological, and In Vivo Function Characterization of B-domain-Deleted Factor VIII," <i>Blood</i> , Vol 81: 2925-2935 (1993).
	PLANTIER J.L. et al., "A factor VIII minigene comprising the truncated intron I of factor IX highly improves the <i>in vitro</i> production of factor VIII," <i>Thrombosis and Haemostasis</i> , Vol. 86(2):596-603 (2001).
	PLANTIER, J.L., et al., "A Combination of Truncated Factor IX Intron 1 Highly Improves FVIII Production," <i>Blood</i> , Vol. 94., No. 10, Supp. 1, Part 1: 454a, Forty-first Annual Meeting of the American Society of Hematology. Abstract No. 2021 (1999).
	ROBERTS, Harold R., "Molecular Biology of Hemophilia B," <i>Thrombosis and Haemostasis</i> , Vol. 70: 1-9 (1993).
	SARVER et al., "Stable Expression of Recombinant Factor VIII Molecules Using a Bovine Papillomavirus Vector," <i>DNA</i> , Vol. 6(6):553-564 (1987).
	TOOLE, J.J., et al., "A Large Region (≈95 kDa) of Human Factor VIII is Dispensable for In Vitro Procoagulant Activity," <i>Proc. Nat'l. Acad. Sci. USA</i> , Vol. 83:5939-5942 (1986).
	TOOLE, J.J. et al., "Molecular cloning of a cDNA encoding human antihaemophilic factor," <i>Nature</i> , Vol. 312: 342-347 (1984).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



OMB No. 0651-0011

**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

Atty. Docket No.	06478.1441-01	Serial No.	09/880,887
Applicant	Claude NÉGRIER et al.		
Filing Date	June 15, 2001	Group:	1636

	VEHAR, G.A. et al., "Structure of human factor VIII," <i>Nature</i> , Vol. 312: 337-342 (1984).
	VLOT, A.J. et al., "Factor VIII and von Willebrand Factor," <i>Thromb Haemost.</i> Vol. 79: 456-465 (1998).
	WOOD et al., "Expression of active human factor VIII from recombinant DNA clones," <i>Nature</i> , 312:330-337 (1984)

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449 Page 4 of 4	Patent and Trademark Office - U.S. Department of Commerce